Source-grounded facts extracted from CURIS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CURIS INC shareholders approved Adjournment of Annual Meeting, if necessary, to solicit additional proxies.
“The proposal to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event there are insufficient votes to approve Proposal 4 was approved: For Against Abstain Broker Non-Votes 22,767,275 774,603 67,500 —”
CURIS INC shareholders approved Amendment to Certificate of Incorporation to increase number of authorized shares of common stock.
“The amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock was adopted and approved: For Against Abstain Broker Non-Votes 21,649,122 1,768,174 192,082 —”
CURIS INC shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
“The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified: For Against Abstain Broker Non-Votes 23,513,646 62,881 32,851 —”
CURIS INC shareholders approved Nonbinding advisory proposal on the compensation of the Company’s named executive officers.
“A nonbinding advisory proposal on the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non-Votes 16,379,076 346,270 3,997,644 2,886,388”
CURIS INC shareholders approved Election of Class III directors for terms of three years expiring at the 2029 annual meeting.
“The following nominees were elected to the Board as Class III directors for terms of three years expiring at the Company’s 2029 annual meeting of stockholders: Name For Withheld Broker Non-Votes Martyn D. Greenacre 20,415,639 307,351 2,886,388 Kenneth I. Kaitin, Ph.D. 20,520,545 202,445 2,886,388”
CURIS INC: Filed Certificate of Elimination eliminating designated Series A and Series B Preferred Stock series (effective 2026-05-19).
“on May 19, 2026, the Company filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware, which was effective upon filing, eliminating from the Company’s Certificate of Incorporation, the Certificate of Designation with respect to the Company’s Series A Convertible Exchangeable Preferred Stock (the “Series A Preferred Stock”) and the Certificate of Designation with respect to the Company’s Series B Convertible Non-Redeemable Preferred Stock (the “Series B Preferred Stock”).”
CURIS INC: Increased authorized shares of capital stock from 288,757,150 to 572,514,300 and authorized common stock from 283,757,150 to 567,514,300 (effective 2026-05-19).
“On May 19, 2026, Curis, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders adopted and approved an amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase the number of authorized shares of the Company’s capital stock from 288,757,150 to 572,514,300 and the number of authorized shares of its common stock from 283,757,150 to 567,514,300 (the “Certificate of Amendment”).”
CURIS INC reported for the quarter ended March 31, 2026 results: net income net loss of $24.2 million, or $1.25 per share on both a basic and diluted basis, EPS $1.25 per share on both a basic and diluted basis.
“On May 12, 2026, Curis, Inc. announced its financial results for the three-month periods ended March 31, 2026.”
CURIS INC reported Year ended December 31, 2025 results: revenue $9.4 million, net income $7.6 million, EPS $0.58.
“per share on both a basic and diluted basis as compared to a net loss of $9.6 million or $1.25 on both a basic and diluted basis for the same period in 2024. Revenues, net were $9.4 million and $10.9 million for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge”
CURIS INC reported Fourth Quarter 2025 results: revenue $1.1 million, net income $19.4 million, EPS $1.23.
“for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ® . Revenues were $1.1 million and $3.3 million for the fourth quarters of 2025 and 2024, respectively. As previously announced, on November 6, 2025, the Company sold to TPC Investments Royalty LLC, a limited”
CURIS INC: Increased authorized shares of capital stock from 73,343,750 to 288,757,150 and common stock from 68,343,750 to 283,757,150 (effective 2026-03-17).
“the Company’s stockholders adopted and approved an amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s capital stock from 73,343,750 to 288,757,150 and the number of authorized shares of our common stock from 68,343,750 to 283,757,150”
CURIS INC received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).
“February 3, 2026, Curis, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(2) (“MVLS Rule”) and is in full compliance with the terms set forth by the Nasdaq Hearings Panel (the “Panel”). Pursuant to Listing Rule 5815(d)(4)(A), the Company will be subject to a Discretionary Panel Monitor for a period of one-year. If, within the one-year monitoring period, the Listing Qualifications Department (“Staff”) finds the Company again out of compliance with any of Nasdaq’s Listing”
CURIS INC issued 26,926,675 shares of Common Stock of warrant to the purchasers named therein for purchase price of $1,000.00 per Security.
“shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the”
CURIS INC issued 26,926,675 shares of the Company’s common stock of warrant to the purchasers named therein for purchase price of $1,000.00 per Security.
“shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the”
CURIS INC issued 20,195 shares of its Series B convertible non-redeemable preferred stock of preferred stock to the purchasers named therein for purchase price of $1,000.00 per Security.
“shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the”
CURIS INC: Filed Certificate of Designations for Series B Convertible Non-Redeemable Preferred Stock, designating 20,195 shares with specific rights, preferences, and privileges (effective 2026-01-07).
“Pursuant to the terms of the Purchase Agreement, on January 7, 2026 (the “Filing Date”), the Company filed the Certificate of Designations with the Secretary of State of the State of Delaware designating 20,195 shares of its authorized and unissued preferred stock as Series B Preferred Stock.”
CURIS INC entered into Securities Purchase Agreement with the purchasers named therein valued at up to approximately $80.8 million (effective 2026-01-07).
“On January 7, 2026, Curis, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell an aggregate of (i) 20,195 shares of its Series B convertible non-redeemable preferred stock, par value $0.01 per share (the “Series B Preferred Stock”), (ii) Series A warrants”
CURIS INC completed a disposition involving Royalty Pharma plc for $125,000,000 (closed 2025-11-06).
“On November 6, 2025 (the “Closing Date”), the Company completed its sale of the Erivedge Business.”
CURIS INC received a nasdaq extension granted notice regarding market value (rules 5550(b)(2)).
“October 20, 2025, the Company received written notice from Nasdaq indicating that the Panel has granted the Company an exception until November 14, 2025 (“Exception Period”) to regain compliance with the MVLS Requirement. During the Exception Period, the Company is required to provide prompt notification of any significant events that occur during this period that may affect the Company’s compliance with Nasdaq requirements including any event that may call into question the Company’s ability to meet the terms of the exception granted. The Panel reserves the right to reconsider the terms of th”
CURIS INC received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“August 21, 2025, the Company received notice from the Staff stating that, because the Company has not regained compliance with the MVLS Requirement, its securities would be delisted from The Nasdaq Capital Market unless the Company timely appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”) by August 28, 2025. The Company intends to make a timely request for a hearing before the Panel to appeal the Staff’s determination. The Company’s request for a hearing will stay the suspension and delisting of the Company’s securities by the Sta”
CURIS INC: Modified Section 3.8 to reduce stockholder meeting quorum from a majority to one-third of shares entitled to vote (effective 2025-05-20).
“the amendment effected by the Amended and Restated By-Laws modified Section 3.8 thereof to provide that one-third (1/3) of the shares, instead of a majority, of capital stock of the Company issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board in its sole discretion, or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business”
CURIS INC: Increased authorized shares of capital stock from 39,171,875 to 73,343,750 and common stock from 34,171,875 to 68,343,750 (effective 2025-05-20).
“the Company’s stockholders adopted and approved an amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s capital stock from 39,171,875 to 73,343,750 and the number of authorized shares of the Common Stock from 34,171,875 to 68,343,750 (the “Increase in Authorized Shares Certificate of Amendment”).”
CURIS INC received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
“February 21, 2025, Curis, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”), as the market value of the Company’s listed securities had been below $35,000,000 for the last 30 consecutive business days. The Notice indicated that Nasdaq Listing Rule 5810(c)(3)(C) provides the Company a compliance period of 180 calendar days, or until August 20, 2025 (the “Compliance Period”), to regain compliance with the MVLS R”
CURIS INC reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income net loss of $11.9 million or $2.05 per share on both a basic and diluted basis.
“For the first quarter of 2024, Curis reported a net loss of $11.9 million or $2.05 per share on both a basic and diluted basis as compared to $11.6 million or $2.39 per share on both a basic and diluted basis, for the same period in 2023. Revenues for the first quarter of 2024 were $2.1 million as compared to $2.3 million for the same period in 2023.”
CURIS INC reported financial results for full year and quarter ended December 31, 2023.
“On February 8, 2024, Curis, Inc. announced its financial results for the full year and quarter ended December 31, 2023.”
CURIS INC reported third quarter of 2023 results: revenue $2.8 million, net income $12.2 million, EPS $2.13.
“to a net loss of $45.3 million or $9.82 per share on both a basic and diluted basis for the same period in 2022. Revenues for the third quarters of 2023 and 2022 were both $2.8 million. Revenues for both periods consist of royalty revenues from Genentech and Roche's sales of Erivedge®. Revenues for the nine months ended September 30, 2023 and 2022 were both”
CURIS INC: Certificate of Amendment to effect a 1-for-20 reverse stock split of issued Common Stock, filed on September 28, 2023, effective at 5:00 p.m. Eastern Time on that date (effective 2023-09-28).
“On September 28, 2023 (the “Effective Date”), the Company filed the Reverse Stock Split Certificate of Amendment with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time on the Effective Date, the Reverse Stock Split.”
CURIS INC: Certificate of Amendment to increase authorized shares of capital stock from 232,812,500 to 460,625,000 and common stock from 227,812,500 to 455,625,000, effective upon filing on September 26, 2023 (effective 2023-09-26).
“On September 26, 2023, Curis, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”), as a virtual web conference at www.virtualshareholdermeeting.com/CRIS2023SM, at which a quorum was present by proxy. At the Special Meeting, the Company’s stockholders adopted and approved an amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s capital stock from 232,812,500 to 460,625,000 and the number of authorized shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), from 227,812,500 to 455,625,000 (the “Increase in Authorized Shares Certificate of Amendment”).”
CURIS INC shareholders approved Adjournment of the Special Meeting to permit further solicitation if necessary.
“The proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, the adoption and approval of the Authorized Shares Proposal or the Reverse Stock Split Proposal was approved: For Against Abstain 73,292,827 11,478,067 697,955”
CURIS INC shareholders approved Reverse stock split of issued shares of Common Stock at a ratio between 1-for-5 and 1-for-25, with board discretion on ratio and timing.
“The amendment to the Company’s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the issued shares of Common Stock, by a ratio of not less than 1-for-5 and not more than 1-for-25, and a proportionate reduction in the number of authorized shares of capital stock and Common Stock, such ratio and the implementation and timing of such reverse stock split to be determined in the discretion of the Company’s board of directors without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split Proposal”) was adopted and approved: For Against Abstain 73,031,848 12,284,263 152,738”
CURIS INC shareholders approved Increase the number of authorized shares of capital stock from 232,812,500 to 460,625,000 and authorized shares of Common Stock from 227,812,500 to 455,625,000.
“The amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s capital stock from 232,812,500 to 460,625,000 and the number of authorized shares of Common Stock from 227,812,500 to 455,625,000 (the “Authorized Shares Proposal”) was adopted and approved: For Against Abstain 71,422,423 13,859,070 187,356”
CURIS INC: Effected a 1-for-20 reverse stock split and proportionately reduced authorized common shares to 22,781,250 (effective 2023-09-28).
“On September 28, 2023 (the “Effective Date”), the Company filed the Reverse Stock Split Certificate of Amendment with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time on the Effective Date, the Reverse Stock Split.”
CURIS INC: Increased authorized shares of capital stock from 232,812,500 to 460,625,000 and common stock from 227,812,500 to 455,625,000 (effective 2023-09-26).
“The Company filed the Increase in Authorized Shares Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on September 26, 2023.”
CURIS INC shareholders approved Adjourn the Special Meeting to permit further solicitation of proxies if needed.
“The proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, the adoption and approval of the Authorized Shares Proposal or the Reverse Stock Split Proposal was approved: For Against Abstain 73,292,827 11,478,067 697,955”
CURIS INC shareholders approved Reverse stock split of issued common stock at a ratio of not less than 1-for-5 and not more than 1-for-25.
“The amendment to the Company’s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the issued shares of Common Stock, by a ratio of not less than 1-for-5 and not more than 1-for-25, and a proportionate reduction in the number of authorized shares of capital stock and Common Stock, such ratio and the implementation and timing of such reverse stock split to be determined in the discretion of the Company’s board of directors without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split Proposal”) was adopted and approved: For Against Abstain 73,031,848 12,284,263 152,738”
CURIS INC shareholders approved Increase authorized shares of capital stock from 232,812,500 to 460,625,000 and common stock from 227,812,500 to 455,625,000.
“The amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s capital stock from 232,812,500 to 460,625,000 and the number of authorized shares of Common Stock from 227,812,500 to 455,625,000 (the “Authorized Shares Proposal”) was adopted and approved: For Against Abstain 71,422,423 13,859,070 187,356”
CURIS INC reported financial results for six months ended June 30, 2023.
“On August 3, 2023, Curis, Inc. announced its financial results for the three- and six-month periods ended June 30, 2023.”
CURIS INC reported financial results for second quarter ended June 30, 2023.
“On August 3, 2023, Curis, Inc. announced its financial results for the three- and six-month periods ended June 30, 2023.”
CURIS INC entered into Purchase Agreement with certain institutional investors valued at approximately $15.1 million (effective 2023-07-05).
“On July 5, 2023, Curis, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Offering”), an aggregate of 18,409,756 shares of common stock, $0.01 par value per share, of the Company (the “Common Stock”), at a purchase price per share of $0.82 (the “Shares”). The aggregate gross proceeds to the Company from the Registered Offering are expected to be approximately $15.1 million, before deducting fees payable to the placement agents and other estimated offering expenses payable by the Company.”
CURIS INC shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor at the 2023-05-23 meeting.
“4. The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified: For Against Abstain 60,410,407 818,940 1,103,482”
CURIS INC shareholders approved Advisory vote on frequency of say-on-pay at the 2023-05-23 meeting.
“3. The stockholders recommended, in a nonbinding advisory vote, that future advisory votes on the compensation of the Company’s named executive officers be held every one year: Every 1 Year Every 2 Years Every 3 Years Abstain Broker Non-votes 30,138,922 553,855 411,702 700,202 30,528,148”
CURIS INC shareholders approved Advisory vote on executive compensation at the 2023-05-23 meeting.
“2. A nonbinding advisory proposal on the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non-votes 27,694,106 2,897,742 1,212,833 30,528,148”
CURIS INC shareholders approved Election of Class III directors at the 2023-05-23 meeting.
“1. The following nominees were elected to the Company’s Board of Directors (the “Board”) as Class III directors for terms of three years expiring at the 2026 annual meeting of stockholders: Name For Withheld Broker Non-votes Martyn D. Greenacre 30,381,457 1,423,224 30,528,148 Kenneth I. Kaitin, Ph.D 26,754,025 5,050,656 30,528,148”
CURIS INC reported the first quarter ended March 31, 2023 results: revenue $2.3 million, net income a net loss of $11.6 million, EPS $0.12 per share on both a basic and diluted basis.
“and diluted basis as compared to $16.1 million or $0.18 per share on both a basic and diluted basis, for the same period in 2022. Revenues for the first quarter of 2023 were $2.3 million as compared to $2.1 million for the same period in 2022. Revenues for both periods consist of royalty revenues from Genentech's and Roche's sales of Erivedge®. Research and”
CURIS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“October 21, 2022, Curis, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company was provided an initial period of 180 cal”
CURIS INC reported fourth quarter ended December 31, 2022 vs fourth quarter ended December 31, 2021 results: revenue 2.9 million vs 3.1 million, net income net loss of 11.3 million vs net loss of 13.6 million, EPS 0.12 per share loss vs 0.15 per share loss.
“Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®. Revenues for the fourth quarters of 2022 and 2021 were $2.9 million and $3.1 million, respectively. Costs of royalties which relate to third-party university patent licensors in connection with Genentech and Roche's Erivedge net sales, for the”
CURIS INC reported full year ended December 31, 2022 vs full year ended December 31, 2021 results: revenue 10.2 million vs 10.6 million, net income net loss of 56.7 million vs net loss of 45.4 million, EPS 0.61 per share loss vs 0.50 per share loss.
“to a net loss of $13.6 million or $0.15 per share on both a basic and diluted basis, for the same period in 2021. Revenues, net for the year ended December 31, 2022, were $10.2 million as compared to $10.6 million for the same period in 2021. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®.”
CURIS INC: Amended and restated by-laws to eliminate stockholder list requirement at meetings, address remote meeting adjournment due to technical failure, add exclusive forum provision, revise advance notice deadlines and procedural mechanics for stockholder nominations and proposals, add emergency by-law pro (effective 2023-03-07).
“On March 7, 2023, the board of directors (the “Board”) of the Company approved an amendment and restatement of the Company’s Amended and Restated By-Laws (as so amended and restated, the “Amended and Restated By-Laws”), effective immediately.”
CURIS INC reported third quarter ended September 30, 2022 results: revenue $2.8 million, net income net loss of $13.3 million, EPS $0.14 per share on both a basic and diluted basis.
“to a net loss of $31.8 million, or $0.35 per share on both a basic and diluted basis for the same period in 2021. Revenues, net for the third quarter of 2022 and 2021 were $2.8 million and $3.0 million, respectively. Revenues, net for the nine months ended September 30, 2022 were $7.3 million as compared to $7.5 million for the same period in 2021. Revenues for”
Anne E. Borgman, M.D. was elected as Class I Director at CURIS INC.
“On October 12, 2022 , the Board of Directors (“Board”) of Curis, Inc. (the “Company”) elected Anne E. Borgman, M.D., to serve as a class I director until the 2024 Annual Meeting of Stockholders and thereafter until her successor is duly elected and qualified.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.